PIMREG and autoimmune disease: As such initiating Cat-S inhibition even after the onset of clinically apparent autoimmune disease not only specifically suppresses the central immunological pathomechanism shared by all autoimmune diseases17, i.e. MHC-II-mediated autoantigen presentation but also protects the peripheral vascular interface and thereby suppresses leukocyte recruitment, tissue inflammation and remodeling of organs affected by autoimmune injury, especially when treatment is initiated early.